Clinical Trial Update: A Prospective, Non-interventional Study of JAKAVI® (Ruxolitinib) Treatment in Patients With Polycythemia Vera

View source ↗

Summary

A completed prospective, non-interventional study evaluating JAKAVI (ruxolitinib) for Polycythemia Vera. Sponsor: Novartis Pharmaceuticals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Polycythemia Vera

Drugs mentioned

• Jakavi (ruxolitinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Polycythemia Vera | Status: COMPLETED